Skip to main content
Incyte10-Q: Product launch

FDA Approves JAKAFI XR Extended Release Tablets in May 2026 for MF, PV, and GVHD

Source: Autobound Signal API · 75 signals tracked for Incyte · updated

Get Incyte's live signals in Claude or ChatGPT, or by API

AskWhat changed at Incyte this week? Use Autobound signals for incyte.com.

What happened

In May 2026, the FDA approved JAKAFI XR extended release tablets across intermediate/high-risk MF, PV, and acute/chronic GVHD indications.

Source

SEC EDGARJul 28, 2026

Quarterly report (Form 10-Q)

Incyte 10-Q for Quarter ended Jun 30, 2026

Filing excerpt

In May 2026, the FDA approved JAKAFI XR (ruxolitinib) extended release tablets for the treatment of adults with intermediate- or high-risk MF, adults with PV who have had an inadequate response to or are intolerant to hydroxyurea, as well as adults and children aged 12 years and older with steroid-refractory acute GVHD or chronic GVHD after failure of one or two lines of systemic therapy.

sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htmRead the full source

Other signals in this filing (1)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Product launch

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Jun 30, 2026
Fiscal year end
06/30
Filed
Jul 28, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
879169
Accession number
0000879169-26-000056
Timeframe
Current quarter
Quarter
Q2
Filing year
2026
Period end date
Jun 30, 2026
Why it matters
Go-to-market support
Signal category
Strategic

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
85%
Sentiment
Positive
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
productLaunch

Use this data

Get every 10-Q signal for Incyte and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/fc355afd-4d2d-444c-b38a-17436230d699 returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.

{
  "signal_id": "fc355afd-4d2d-444c-b38a-17436230d699",
  "signal_type": "sec-10q",
  "signal_subtype": "productLaunch",
  "detected_at": "2026-11-09T06:30:46.095+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "detail": "In May 2026, the FDA approved JAKAFI XR extended release tablets across intermediate/high-risk MF, PV, and acute/chronic GVHD indications. This launch offers GTM commercialization, specialized packaging, and patient adherence technology vendors engagement opportunities.",
    "metrics": {
      "timeframe": "current_quarter"
    },
    "quarter": "Q2",
    "summary": "FDA Approves JAKAFI XR Extended Release Tablets in May 2026 for MF, PV, and GVHD",
    "excerpts": "In May 2026, the FDA approved JAKAFI XR (ruxolitinib) extended release tablets for the treatment of adults with intermediate- or high-risk MF, adults with PV who have had an inadequate response to or are intolerant to hydroxyurea, as well as adults and children aged 12 years and older with steroid-refractory acute GVHD or chronic GVHD after failure of one or two lines of systemic therapy.",
    "relevance": 0.85,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm",
    "filing_date": "2026-07-28",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "06/30",
    "period_end_date": "2026-06-30",
    "sales_relevance": "Go-to-market support",
    "signal_category": "strategic",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.